Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 9, 2016, Pages 2299-2311

  La Torre, Giuseppe ^a   Mannocci, Alice ^a   Saulle, Rosella ^a   Colamesta, Vittoria ^a   Meggiolaro, Angela ^a   Mipatrini, Daniele ^a   Sinopoli, Alessandra ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

cost benefit; cost effectiveness; cost utility; economic evaluation; HBV vaccination

Indexed keywords

HEPATITIS B VACCINE;

BIBLIOGRAPHIC DATABASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; ECONOMIC EVALUATION; HEPATITIS B; HUMAN; INCOME; NON COMMUNICABLE DISEASE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW (TOPIC); VACCINATION; COST OF ILLNESS; ECONOMICS; GLOBAL HEALTH; IMMUNOLOGY;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; GLOBAL HEALTH; HEPATITIS B; HEPATITIS B VACCINES; HUMANS;

EID: 84987849568     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1166328     Document Type: Review

References (129)

1. A.P.Venook, C.Papandreou, J.Furuse, L.L.de Guevara. The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective. Oncologist 2010; 15 (Suppl 4):5-13; PMID:21115576; http://dx.doi.org/10.1634/theoncologist.2010-S4-05
2. WHO. Revised WHO position paper on hepatitis B vaccine, Oct 2009 – the abridged version - (draft 22 Sept 2009). Available from:http://www.who.int/immunization/HepB_position_paper_oct09_summary.pdf
3. M.F.Drummond. Principles of economic appraisal in health care Oxford University Press, Oxford, 1980
4. D.Lahaye, P.Strauss, C.Baleux, W.van Ganse. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987; 2(8556):441-3; PMID:2887738; http://dx.doi.org/10.1016/S0140-6736(87)90971-8
5. G.Liguori, F.Gallé, P.Marinelli. Epidemiology of hepatitis C virus infection in the world, Europe, Italy and Campania:an overview. Ital J Public Health 2004; 1(1–2):40-6
6. WHO. Hepatitis B (Fact sheet N°204). Available from:http://www.who.int/mediacentre/factsheets/fs204/en/ (updated July 2013)
7. G.Di Giuseppe, C.G.Nobile, P.Marinelli, I.F.Angelillo. A survey of knowledge, attitudes, and behavior of Italian dentists toward immunization. Vaccine 2007; 25(9):1669-75; PMID:17129642; http://dx.doi.org/10.1016/j.vaccine.2006.10.056
8. M.Piazza. Experimental Viral Hepatitis. Charles C. Thomas Pubbl. Illinois, 1969
9. M.Piazza, V.Guadagnino, L.Picciotto, G.Borgia, S.Nappa. Contamination by hepatitis B surface antigen in dental surgeries. Br Med J (Clin Res Ed). 1987 Aug 22; 295(6596):473-4; PMID:3117175
10. M.Piazza. Universal hepatitis B vaccination. Lancet Infect Dis 2008 Feb; 8(2):88-9; PMID:18222158; http://dx.doi.org/10.1016/S1473-3099(08)70005-7
11. P.Beutels. Economic evaluations of hepatitis B immunization:a global review of recent studies (1994–2000). Health Econ 2001; 10(8):751-74; PMID:11747055; http://dx.doi.org/10.1002/hec.625
12. H.A.Tu, H.J.Woerdenbag, S.Kane, A.Riewpaiboon, M.van Hulst, M.J.Postma. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 2009; 8(7):907-20; PMID:19538116; http://dx.doi.org/10.1586/erv.09.53
13. W.Zhang, Z.Guo, L.Zhang, Z.Liu, J.Li, Z.Ji, R.Xu, N.Zhao, F.Li, X.Chen, et al. Maternal immunization promotes the immune response of neonates towards hepatitis B vaccine. J Viral Hepat 2013 Dec; 20(12):875-81; PMID:24304457; http://dx.doi.org/10.1111/jvh.12103
14. N.H.Park, Y.H.Chung, H.S.Lee. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010; 53(1):20-8; PMID:20068337; http://dx.doi.org/10.1159/000252780
15. Z.Luo, L.Li, B.Ruan. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012 Feb; 16(2):e82-8; PMID:22178658; http://dx.doi.org/10.1016/j.ijid.2011.10.009
16. B.Mao, M.K.Patel, K.Hennessey, R.J.Duncan, K.Wannemuehler, S.C.Soeung. Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia. Vaccine 2013Sep 13; 31(40):4459-64; PMID:23684825; http://dx.doi.org/10.1016/j.vaccine.2013.05.009
17. T.H.Nguyen, M.H.Vu, V.C.Nguyen, L.H.Nguyen, K.Toda, T.N.Nguyen, S.Dao, K.A.Wannemuehler, K.A.Hennessey. A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine 2013; 32(2):217-22
18. WHO. Hepatitis B (Fact sheet N°204). Available from:http://www.who.int/mediacentre/factsheets/fs204/en/ (updated July 2013)
19. CDC. Global Routine Vaccination Coverage, 2011. Morbidity and Mortality Weekly Report (MMWR) 2012; 61(43):883-885
20. B.S.Bloom, A.L.Hillman, A.M.Fendrick, J.S.Schwartz. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993; 118(4):298-306; PMID:8420448; http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00009
21. S.M.Holliday, D.Faulds. Hepatitis B vaccine:a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994; 5(2):141-71; PMID:10146907; http://dx.doi.org/10.2165/00019053-199405020-00008
22. F.Antoñanzas, R.Garuz, J.Rovira, F.Antón, C.Trinxet, E.Navas, L.Salleras. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. Pharmacoeconomics 1995; 7(5):428-43; http://dx.doi.org/10.2165/00019053-199507050-00007
23. H.S.Margolis, P.J.Coleman, R.E.Brown, E.E.Mast, S.H.Sheingold, J.A.Arevalo. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1202-9; http://dx.doi.org/10.1001/jama.1995.03530150025029
24. P.Van Damme, G.Tormans, P.Beutels, E.Van Doorslaer. Hepatitis B prevention in Europe:a preliminary economic evaluation. Vaccine 1995; 13(S1):54-7; PMID:7762278; http://dx.doi.org/10.1016/0264-410X(95)80053-G
25. R.A.Hicks, J.W.Cullen, M.A.Jackson, V.F.Burry. Hepatitis B virus vaccine. Cost-benefit analysis of its use in a children's hospital. Clin Pediatr (Phila) 1989; 28(8):359-65; PMID:2527103; http://dx.doi.org/10.1177/000992288902800805
26. W.Edmunds, A.Dejene, Y.Mekonnen, M.Haile, W.Alemnu, D.Nokes. The cost of integrating hepatitis B virus vaccine into national immunization programmes:a case study from Addis Ababa. Health Policy Plan 2000; 15(4):408-16; PMID:11124244; http://dx.doi.org/10.1093/heapol/15.4.408
27. R.Fernández Barboza, D.Rivero, B.Echeverría, I.V.Machado. Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela. Bol Oficina Sanit Panam 1991; 111(1):16-23
28. E.J.Hatziandreu, A.Hatzakis, S.Hatziyannis, M.A.Kane, M.C.Weinstein. Cost-effectiveness of hepatitis-B vaccine in Greece. A country of intermediate HBV endemicity. Int J Technol Assess Health Care 1991; 7(3):256-62; PMID:1834601; http://dx.doi.org/10.1017/S026646230000564X
29. R.A.Pennie, A.M.O'Connor, C.S.Dulberg, A.Bottiglia, P.Manga, C.Y.Kang. Low-cost hepatitis B vaccine improves uptake among self-paying health-care students. J Med Virol 1992; 37(1):48-53; PMID:1535653; http://dx.doi.org/10.1002/jmv.1890370108
30. G.La Torre, R.Saulle, B.Unim. Hepatitis B immunization in health care workers:needs and opportunities. Hepatitis Monthly 2011; 11(8):664-5; PMID:22140393; http://dx.doi.org/10.5812/kowsar.1735143X.1504
31. F.Fabrizi, S.Di Filippo, D.Marcelli, I.Guarnori, L.Raffaele, M.Crepaldi, G.Erba, F.Locatelli. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72(4):536-43; PMID:8730417; http://dx.doi.org/10.1159/000188935
32. G.La Torre, E.De Vito, E.Langiano, P.Petta, G.Colarossi, L.Cipriani, M.Tucciarone, G.Ricciardi. Epidemiology of hepatitis C virus antibodies in blood donors from the province of Latina, Italy. Eur J Epidemiol 2003; 18(7):691-4; PMID:12952144; http://dx.doi.org/10.1023/A:1024817417635
33. G.Da Villa, G.Sepe. Immunization programme against hepatitis B virus infection in Italy:cost-effectiveness. Vaccine 1999; 17:1734-8; PMID:10194831; http://dx.doi.org/10.1016/S0264-410X(98)00414-9
34. G.La Torre, N.Nicolotti, C.de Waure, G.Chiaradia, M.L.Specchia, A.Mannocci, W.Ricciardi. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. Virology J 2008; 5:84; http://dx.doi.org/10.1186/1743-422X-5-84
35. D.Wiewióra-Pilecka. Cost-benefit analysis of the Polish hepatitis B prevention Programme. Vaccine 2000; 18:S52-4; http://dx.doi.org/10.1016/S0264-410X(99)00465-X
36. A.Harris, K.Yong, M.Kermode. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB):a decision analytic approach to cost effectiveness. Aust N Z J Public Health 2001; 25(3):222-9; PMID:11494989; http://dx.doi.org/10.1111/j.1467-842X.2001.tb00566.x
37. B.M.Yang, S.W.Paik, O.S.Hahn, D.H.Yi, M.S.Choi, S.Payne. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001; 16:301-8; PMID:11339422; http://dx.doi.org/10.1046/j.1440-1746.2001.02443.x
38. S.Saab, S.R.Weston, D.Ly, M.Brezina, H.F.Yee, Jr, S.H.Han, G.Gitnick. Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients. Vaccine 2002; 20(25–26):3230-5; PMID:12163275; http://dx.doi.org/10.1016/S0264-410X(02)00249-9
39. P.Adibi, M.Rezailashkajani, D.Roshandel, N.Behrouz, S.Ansari, M.H.Somi, S.Shahraz, M.R.Zali. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect Dis 2004 Sep 4; 4:31; PMID:15347430; http://dx.doi.org/10.1186/1471-2334-4-31
40. T.Vimolket, Y.Poovorawan. An economic evaluation of universal infant Vaccination strategies against Hepatitis B in Thailand:an analytic decision approach to Cost-effectiveness. Southeast Asian J Trop Med Public health 2005; 36(3):693-9; PMID:16124440
41. S.Y.Kim, K.Billah, T.A.Lieu, M.C.Weinstein. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006; 30(6):498-506; PMID:16704944; http://dx.doi.org/10.1016/j.amepre.2006.01.017
42. D.W.Hutton, D.Tan, S.K.So, M.L.Brandeau. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147(7):460-9; PMID:17909207; http://dx.doi.org/10.7326/0003-4819-147-7-200710020-00004
43. R.Jakiche, M.E.Borrego, D.W.Raisch, G.V.Gupchup, M.A.Pai, A.Jakiche. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci 2007; 333(1):26-34; PMID:17220691; http://dx.doi.org/10.1097/00000441-200701000-00004
44. L.Tilson, L.Thornton, D.O'Flanagan, H.Johnson, M.Barry. Cost effectiveness of hepatitis B vaccination strategies in Ireland:an economic evaluation. Eur J Public Health 2007; 18(3):275-82; PMID:18160389; http://dx.doi.org/10.1093/eurpub/ckm123
45. Y.Hu, L.E.Grau, G.Scott, K.H.Seal, P.A.Marshall, M.Singer, R.Heimer. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008; 35(1):25-32; PMID:18541174; http://dx.doi.org/10.1016/j.amepre.2008.03.028
46. M.K.Miriti, K.Billah, C.Weinbaum, J.Subiadur, R.Zimmerman, P.Murray, R.Gunn, J.Buffington. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US. Public Health Rep 2008; 123(4):504-13; PMID:18763413
47. H.F.Hung, T.H.H.Chen. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination:An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009; 27:6770-6; PMID:19735755; http://dx.doi.org/10.1016/j.vaccine.2009.08.082
48. J.M.Fischinger, B.Stephan, K.Wasserscheid, H.Eichler, B.C.Gärtner. A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus. Vaccine 2010; 28(49):7797-802; PMID:20875488; http://dx.doi.org/10.1016/j.vaccine.2010.09.037
49. M.R.Siddiqui, N.Gay, W.J.Edmunds, M.Ramsay. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011; 29(3):466-75; PMID:21073988; http://dx.doi.org/10.1016/j.vaccine.2010.10.075
50. C.Klingler, A.I.Thoumi, V.S.Mrithinjayam. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine 2012; 31(1):252-9; PMID:22902676; http://dx.doi.org/10.1016/j.vaccine.2012.08.007
51. A.Savova, G.Petrova, A.Gotseva, A.Kurcatova, M.Koguharova. Economic analysis 20 years after the introduction of universal HBV immunisation in Bulgaria. Biotechnol Biotechnol Eq 2012; 26(1):2811-6; http://dx.doi.org/10.5504/BBEQ.2011.0141
52. H.A.T.Tu, R.de Vries, H.J.Woerdenbag, S.C.Li, H.H.Le, M.van Hulst, M.J.Postma. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam:Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making. Value in Health Regional Issues 2012; 1:7-14; http://dx.doi.org/10.1016/j.vhri.2012.03.007
53. S.C.Chen, M.Toy, J.M.Yeh, J.D.Wang, S.Resch. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013; 131(4):e1135-43; PMID:23530168; http://dx.doi.org/10.1542/peds.2012-1262
54. T.J.Hoerger, S.Schillie, J.S.Wittenborn, C.L.Bradley, F.Zhou, K.Byrd, T.V.Murphy. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013; 36(1):63-9; PMID:22933435; http://dx.doi.org/10.2337/dc12-0759
55. R.K.Kuan, R.Janssen, W.Heyward, S.Bennett, R.Nordyke. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B→ vaccine. Vaccine 2013; 31(37):4024-32; PMID:23707166; http://dx.doi.org/10.1016/j.vaccine.2013.05.014
56. S.Q.Lu, S.M.McGhee, X.Xie, J.Cheng, R.Fielding. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine 2013; 31(14):1864-9; PMID:23384752; http://dx.doi.org/10.1016/j.vaccine.2013.01.020
57. G.La Torre, D.Vezzo, R.Arcese, C.Bongiovanni, G.Capelli, G.Ricciardi. Occurrence and correlates of HIV and Hepatitis B/C virus infections among prisoners of Southern Lazio, Italy. Ital J Public Health 2004; 1:33-9
58. S.A.SeyedAlinaghi, P.Kheirandish, N.Karami, S.Salem, H.Shirzad, M.R.Jahani, M.R.SeyedAhmadian, P.Valiollahi, M.Hosseini, M.Mohraz, W.McFarland. High prevalence of chronic hepatitis B infection among injection drug users in Iran:the need to increase vaccination of adults at risk. Acta Med Iran 2010 Jan–Feb; 48(1):58-60; PMID:21137671
59. L.Y.Hwang, C.Z.Grimes, T.Q.Tran, A.Clark, R.Xia, D.Lai, C.Troisi, M.Williams. Accelerated hepatitis B vaccination schedule among drug users:a randomized controlled trial. J Infect Dis 2010 Nov 15; 202(10):1500-9; PMID:20936979; http://dx.doi.org/10.1086/656776
60. K.Chaiklang, J.Wipasa, R.Chaiwarith, J.Praparattanapan, K.Supparatpinyo. Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults:A Randomized, Controlled Trial. PLoS One 2013 Nov 12; 8(11):e80409; PMID:24265819; http://dx.doi.org/10.1371/journal.pone.0080409
61. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011 Dec 23; 60(50):1709-11; PMID:22189894
62. O.E.Simani, G.Leroux-Roels, G.François, R.J.Burnett, A.Meheus, M.J.Mphahlele. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009 Jan 1; 27(1):146-51; PMID:18940220; http://dx.doi.org/10.1016/j.vaccine.2008.10.004
63. A.Hodgson, A.A.Forgor, D.Chandramohan, Z.Reed, F.Binka, C.Bevilacqua, D.Boutriau, B.Greenwood. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 2008 May 14; 3(5):e2159; PMID:18478093; http://dx.doi.org/10.1371/journal.pone.0002159
64. R.Montesano. Hepatitis B immunization and hepatocellular carcinoma:The Gambia Hepatitis Intervention Study. J Med Virol 2002 Jul; 67(3):444-6; PMID:12116042; http://dx.doi.org/10.1002/jmv.10093
65. H.C.Whittle, N.Maine, J.Pilkington, M.Mendy, M.Fortuin, J.Bunn, L.Allison, C.Howard, A.Hall. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995 Apr 29; 345(8957):1089-92; PMID:7715343; http://dx.doi.org/10.1016/S0140-6736(95)90822-6
66. J.L.Excler, B.Yvonnet, Y.Gaye, A.Monnereau, J.L.Mangin, M.Schlumberger, F.Mireux, A.B.Gaye, L.C.Sarr. Inclusion of hepatitis B vaccination in the Expanded Program of Immunization:feasibility study in the medical region of Kolda (Senegal). Sante 1995 Jan–Feb; 5(1):37-42; PMID:7894828
67. P.Coursaget, F.Deciron, E.Tortey, F.Barin, J.P.Chiron, B.Yvonnet, C.Diouf, F.Denis, I.Diop-Mar, P.Correa, et al. Immune response to hepatitis B vaccine in infants and newborns:control trial in an endemic area (Senegal). IARC Sci Publ 1984; (63):319-35; PMID:6242150
68. F.Espinoza, M.Tregnaghi, A.Gentile, K.Abarca, J.Casellas, A.Collard, I.Lefevre, J.M.Jacquet. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination:a randomized controlled trial. BMC Infect Dis 2010 Oct 15; 10:297; PMID:20950456; http://dx.doi.org/10.1186/1471-2334-10-297
69. R.N.Gunson, D.Shouval, M.Roggendorf, H.Zaaijer, H.Nicholas, H.Holzmann, A.de Schryver, D.Reynders, J.Connell, W.H.Gerlich, et al. European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs):guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003 Aug; 27(3):213-30; PMID:12878084; http://dx.doi.org/10.1016/S1386-6532(03)00087-8
70. L.Roman∫, S.Paladini, P.Van Damme, A.R.Zanetti. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43 Suppl 1:S2-7; http://dx.doi.org/10.1016/S1590-8658(10)60685-8
71. E.H.Teshale, B.Hepatitis. In Centers For Disease Control and Prevention. CDC Health InFormation For International Travel 2012, OxfordUniversity Press, NewYork, NY, USA, 2012, available at http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm
72. G.P.Garnett. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014 Mar 20; 32(14):1536-42; PMID:24606635; http://dx.doi.org/10.1016/j.vaccine.2013.11.007
73. D.Ieluzzi, L.Covolo, F.Donato, G.Fattovich. Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy. Dig Liver Dis 2014; 46(5):427-32; PMID:24548819
74. International Agency for Research on Cancer. Biological agents. Volume 100B. A review of human carcinogens. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, pp. 93-133, World Health Organization, Geneva, Switzerland, 2012, available at http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php
75. World Health Organization. “Viral hepatitis. Report by the secretariat,” in Proceedings of the 63rd World Health Assembly March2010
76. A.Hatzakis, S.Wait, J.Bruix, M.Buti, M.Carballo, M.Cavaleri, M.Colombo, E.Delarocque-Astagneau, G.Dusheiko, G.Esmat, et al. The state of hepatitis B and C in Europe:report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 Suppl 1:1-16; PMID:21824223; http://dx.doi.org/10.1111/j.1365-2893.2011.01499.x
77. E.Franka, A.H.El-Zoka, A.H.Hussein, M.M.Elbakosh, A.K.Arafa, K.S.Ghenghesh. Hepatitis B virus and hepatitis C virus in medical waste handlers in Tripoli, Libya. J Hosp Infect 2009; 72(3):258-61; PMID:19443080; http://dx.doi.org/10.1016/j.jhin.2009.03.019
78. R.Squeri, V.La Fauci, L.Sindoni, G.Cannav∫, E.Ventura Spagnolo. Study on hepatitis B and C serologic status among municipal solid waste workers in Messina (Italy). J Prev Med Hyg 2006 Sep; 47(3):110-3; PMID:17217188
79. G.1.Dounias, E.Kypraiou, G.Rachiotis, E.Tsovili, S.Kostopoulos. Prevalence of hepatitis B virus markers in municipal solid waste workers in Keratsini (Greece). Occup Med (Lond) 2005 Jan; 55(1):60-3; PMID:15699092; http://dx.doi.org/10.1093/occmed/kqi007
80. A.Hatzakis, P.Van Damme, K.Alcorn, C.Gore, M.Benazzouz, S.Berkane, M.Buti, M.Carballo, H.Cortes Martins, S.Deuffic-Burban, et al. The state of hepatitis B and C in the Mediterranean and Balkan countries:report from a summit conference. J Viral Hepat 2013; 20 Suppl 2:1-20; PMID:23827008; http://dx.doi.org/10.1111/jvh.12120
81. T.A.Marinho, C.L.Lopes, S.A.Teles, M.A.Matos, M.A.Matos, A.G.Kozlowski, M.P.Oliveira, A.M.Silva, R.M.Martins. Epidemiology of hepatitis B virus infection among recyclable waste collectors in central Brazil. Rev Soc Bras Med Trop 2014; 47(1):18-23; PMID:24603732; http://dx.doi.org/10.1590/0037-8682-0177-2013
82. G.Rachiotis, D.Papagiannis, D.Markas, E.Thanasias, G.Dounias, C.Hadjichristodoulou. Hepatitis B virus infection and waste collection:prevalence, risk factors, and infection pathway. Am J Ind Med 2012; 55(7):650-5; PMID:22544469; http://dx.doi.org/10.1002/ajim.22057
83. C.R.Corrao, A.Del Cimmuto, C.Marzuillo, E.Paparo, G.La Torre. Association between waste management and HBV among solid municipal waste workers:a systematic review and meta-analysis of observational studies. Scientific World J 2013 Oct 9; 2013:692083; http://dx.doi.org/10.1155/2013/692083
84. G.Hâţu, M.I.Brumboiu, I.N.Gorgan, I.S.Bocşan. Romanian blood donors screening:is it really necessary and/or mandatory? Rev Med Chir Soc Med Nat Iasi 2013; 117(3):741-6
85. P.Scognamiglio, E.Girardi, M.Fusco, P.Piselli, S.R.Spena, C.Maione, F.A.Pisanti, D.Serraino. Collaborating Study Group. Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy. BMC Infect Dis 2009; 9:86; PMID:19500412; http://dx.doi.org/10.1186/1471-2334-9-86
86. M.A.Pitasi, T.A.Bingham, E.K.Sey, A.J.Smith, E.H.Teshale. Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA. AIDS Behav 2013; 18 Suppl 3:248-55
87. C.Wang, Y.Wang, X.Huang, X.Li, T.Zhang, M.Song, L.Wu, J.Du, X.Lu, S.Shao, et al. Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China. PLoS One 2012; 7(10):e48219; PMID:23133573; http://dx.doi.org/10.1371/journal.pone.0048219
88. D.A.MacKellar, L.A.Valleroy, G.M.Secura, W.McFarland, D.Shehan, W.Ford, M.LaLota, D.D.Celentano, B.A.Koblin, L.V.Torian, et al. Young Men's Survey Study Group. Two decades after vaccine license:hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001; 91(6):965-71; PMID:11392942; http://dx.doi.org/10.2105/AJPH.91.6.965
89. M.1.Carobene, F.Bolcic, M.S.Farías, J.Quarleri, M.M.Avila. HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. J Med Virol 2014; 86(1):64-70; PMID:24123155; http://dx.doi.org/10.1002/jmv.23805
90. L.G.Johnston, T.C.Vaillant, Y.Dolores, H.M.Vales. HIV, hepatitis B/C and syphilis prevalence and risk behaviors among gay, transsexuals and men who have sex with men, Dominican Republic. Int J STD AIDS 2013; 24(4):313-21; PMID:23970664; http://dx.doi.org/10.1177/0956462412472460
91. S.Hahné, R.van Houdt, F.Koedijk, M.van Ballegooijen, J.Cremer, S.Bruisten, R.Coutinho, H.Boot. Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands. PLoS One 2013 Jul 29; 8(7):e67866; http://dx.doi.org/10.1371/journal.pone.0067866
92. K.Taketa, S.Ikeda, N.Suganuma, K.Phornphutkul, S.Peerakome, K.Sitvacharanum, J.Jittiwutikarn. Differential seroprevalences of hepatitis C virus, hepatitis B virus and human immunodeficiency virus among intravenous drug users, commercial sex workers and patients with sexually transmitted diseases in Chiang Mai, Thailand. Hepatol Res 2003; 27(1):6-12; PMID:12957200; http://dx.doi.org/10.1016/S1386-6346(03)00163-3
93. F.Schuelter-Trevisol, G.Custódio, A.C.Silva, M.B.Oliveira, A.Wolfart, D.J.Trevisol. HIV, hepatitis B and C, and syphilis prevalence and coinfection among sex workers in Southern Brazil. Rev Soc Bras Med Trop 2013; 46(4):493-7; PMID:23681430; http://dx.doi.org/10.1590/0037-8682-1364-2013
94. S.D.Praseeda, D.Anuradha, S.S.Jayanthi. A Study on the HBV and the HCV Infections in Female Sex Workers and their Co-Infection with HIV. J Clin Diagn Res 2013; 7(2):234-7; PMID:23543505
95. K.Kassak, Z.Mahfoud, K.Kreidieh, S.Shamra, R.Afifi, S.Ramia. Hepatitis B virus and hepatitis C virus infections among female sex workers and men who have sex with men in Lebanon:prevalence, risk behaviour and immune status. Sex Health 2011 Jun; 8(2):229-33; PMID:21592438; http://dx.doi.org/10.1071/SH10080
96. World Health Organization. Guidance on Prevention of Viral Hepatitis B and C Among People Who Inject Drugs. Geneva, 2012 Jul. Available from:http://www.ncbi.nlm.nih.gov/books/NBK144127/
97. N.Walsh, A.Verster, M.Rodolph, E.A.Akl. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy 2014; S0955-3959(14):00012-7
98. V.Arama, H.Leblebicioglu, K.Simon, J.P.Zarski, C.Niederau, F.Habersetzer, J.Vermehren, W.Bludzin, M.Jinga, S.Ulusoy, et al. the AI; European Longitudinal Chronic Hepatitis B Study Group. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2013; 19(3):245-57
99. K.Owusu-Edusei, Jr, H.W.Chesson, T.L.Gift, G.Tao, R.Mahajan, M.C.Ocfemia, C.K.Kent. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40(3):197-201; PMID:23403600; http://dx.doi.org/10.1097/OLQ.0b013e318285c6d2
100. P.Marcellin, V.Arama, H.Leblebicioglu, J.P.Zarski, S.Zeuzem, S.Mauss, J.Sieklucki, M.Acalovschi, G.Usluer, I.Klauck, et al. the AI; Longitudinal Study Group. Chronic hepatitis B treatment initiation and modification patterns in five European countries:a 2-year longitudinal, non-interventional study. Antivir Ther 2013; 19(3):235-43; PMID:23574686
101. J.Lu, A.Xu, J.Wang, L.Zhang, L.Song, R.Li, S.Zhang, G.Zhuang, M.Lu. Direct economic burden of hepatitis B virus related diseases:evidence from Shandong, China. BMC Health Serv Res 2013; 13:37; PMID:23368750; http://dx.doi.org/10.1186/1472-6963-13-37
102. G.L.Colombo, G.B.Gaeta, M.Vigan∫, S.Di Matteo. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011; 3:37-46; PMID:21935331; http://dx.doi.org/10.2147/CEOR.S16655
103. B.M.Yang, D.J.Kim, K.S.Byun, H.S.Kim, J.W.Park, S.Shin. The societal burden of HBV-related disease:South Korea. Dig Dis Sci 2010; 55(3):784-93; PMID:19333757; http://dx.doi.org/10.1007/s10620-009-0786-4
104. B.M.Yang, C.H.Kim, J.Y.Kim. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004; 38(10 Suppl 3):S153-7; PMID:15602164; http://dx.doi.org/10.1097/00004836-200411003-00007
105. S.C.Ong, S.G.Lim, S.C.Li. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat 2009; 16(1):53-63; PMID:19192158; http://dx.doi.org/10.1111/j.1365-2893.2008.01042.x
106. C.R.Hsieh, C.W.Kuo. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004; 38(10 Suppl 3):S148-52; PMID:15602163; http://dx.doi.org/10.1097/00004836-200411003-00006
107. T.A.Lee, D.L.Veenstra, U.H.Iloeje, S.D.Sullivan. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38(10 Suppl 3):S144-7; PMID:15602162; http://dx.doi.org/10.1097/00004836-200411003-00005
108. J.R.Butler, S.Pianko, R.J.Korda, S.Nguyen, P.J.Gow, S.K.Roberts, S.I.Strasser, W.Sievert. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 2004; 38(10 Suppl 3):S187-92; PMID:15602169; http://dx.doi.org/10.1097/00004836-200411003-00012
109. E.Arnold, Y.Yuan, U.Iloeje, G.Cook. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008; 6(4):231-46; PMID:19382822; http://dx.doi.org/10.1007/BF03256136
110. Y.M.Gagnon, A.R.Levy, U.H.Iloeje, A.H.Briggs. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004; 38(10 Suppl 3):S179-86; PMID:15602168; http://dx.doi.org/10.1097/00004836-200411003-00011
111. H.Kalantari, M.Davari, M.Akbari, S.M.Hejazi, M.Kalantari, S.Zakerin, Z.Shahshahan. The estimation of direct medical costs of treating patients with chronic hepatitis B and C in Iran. Int J Prev Med 2012; 3(3):191-6; PMID:22448312
112. M.Hu, W.Chen. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009; 12 Suppl 3:S89-92; PMID:20586991; http://dx.doi.org/10.1111/j.1524-4733.2009.00636.x
113. G.Zhiqiang, D.Zhaohui, W.Qinhuan, C.Dexian, F.Yunyun, L.Hongtao, U.H.Iloeje. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004; 38(10 Suppl 3):S175-8; PMID:15602167; http://dx.doi.org/10.1097/00004836-200411003-00010
114. A.Wiens, L.Lenzi, R.Venson, M.L.Pedroso, C.J.Correr, R.Pontarolo. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis 2013; 17(4):418-26; PMID:23849851; http://dx.doi.org/10.1016/j.bjid.2012.12.005
115. J.Y.Park, J.Heo, T.J.Lee, H.J.Yim, J.E.Yeon, Y.S.Lim, M.J.Seo, S.H.Ahn, M.S.Lee. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013; 8(3):e57900; PMID:23536775; http://dx.doi.org/10.1371/journal.pone.0057900
116. F.Hulstaert, C.Schwierz, F.Nevens, N.Thiry, M.Gamil, I.Colle, S.Van de Sande, Y.Horsmans. Should chronic hepatitis B be treated as early as possible? Int J Technol Assess Health Care 2013; 29(1):35-41;; PMID:23298548; http://dx.doi.org/10.1017/S0266462312000736
117. M.Robotin, Y.Patton, M.Kansil, A.Penman, J.George. Cost of treating chronic hepatitis B:comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42):6106-13;; PMID:23155339; http://dx.doi.org/10.3748/wjg.v18.i42.6106
118. J.He, J.M.Bowen, F.Xie, R.Goeree. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health 2012; 15(6):894-906; PMID:22999140; http://dx.doi.org/10.1016/j.jval.2012.06.005
119. A.Husic-Selimovic, Z.Vukobrat-Bijedic, M.Bevanda, R.Mesihovic, E.Zerem, S.Ahmetagic, S.Trbojevic, A.Verhaz, Z.Kezic, M.Zildzic, et al. Associations of gastroenterology and hepatology of Bosnia and Herzegovina. Diagnosis and treatment of chronic viral hepatitis B and C:doctrinary approach. Med Arh 2012; 66(3 Suppl 1):56-69; http://dx.doi.org/10.5455/medarh.2012.66.s56-s68
120. M.Toy, F.O.Onder, R.Idilman, G.Kabacam, J.H.Richardus, M.Bozdayi, M.Akdogan, Z.Kuloglu, A.Kansu, S.Schalm, et al. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012; 13(5):663-76; PMID:22815098; http://dx.doi.org/10.1007/s10198-012-0413-8
121. G.La Torre, C.de Waure, G.Chiaradia, A.Mannocci, S.Capri, W.Ricciardi. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010; 28(19):3379-84; PMID:20197141; http://dx.doi.org/10.1016/j.vaccine.2010.02.080
122. W.Ricciardi, B.Dirodi, P.Bonanni, S.Capri, P.Castiglia, G.Gabutti, R.Gasparini, P.Giorgi Rossi, G.Grilli, G.La Torre. Methodological aspects of clinical and economic impact of vaccine interventions and HTA. Focus on HPV vaccination. Ann Ig 2011; 23(5):419-34; PMID:22403995
123. G.La Torre, C.de Waure, G.Chiaradia, A.Mannocci, S.Capri, F.Bamfi, W.Ricciardi. Guidance for future HTA applications to vaccines:the HPV lesson. Hum Vaccin 2011; 7(9):900-4; PMID:21865880; http://dx.doi.org/10.4161/hv.7.9.16084
124. D.Turner, A.Wailoo, K.Nicholson, N.Cooper, A.Sutton, K.Abrams. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7(35):iii-iv, xi-xiii, 1-170; http://dx.doi.org/10.3310/hta7350
125. S.Sehatzadeh. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD):an evidence-based review. Ont Health Technol Assess Ser 2012; 12(3):1-64
126. G.La Torre, C.de Waure, G.Chiaradia, A.Mannocci, M.L.Specchia, N.Nicolotti, W.Ricciardi. The future of best investing in vaccines:the Health Technology Assessment approach. Vaccine 2008; 26(13):1609-10; PMID:18289744; http://dx.doi.org/10.1016/j.vaccine.2008.01.009
127. K.Chalkidou, R.Marten, D.Cutler, T.Culyer, R.Smith, Y.Teerawattananon, F.Cluzeau, R.Li, R.Sullivan, Y.Huang, et al. Health technology assessment in universal health coverage. Lancet 2013; 382(9910):e48-9; PMID:24360390; http://dx.doi.org/10.1016/S0140-6736(13)62559-3
128. A.Liberati, D.G.Altman, J.Tetzlaff, C.Mulrow, P.C.Gøtzsche, J.P.Ioannidis, M.Clarke, P.J.Devereaux, J.Kleijnen, D.Moher. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration. Ital J Public Health 2009; 4:94-131
129. G.La Torre, N.Nicolotti, C.De Waure, W.Ricciardi. Development of a weighted scale to assess the quality of cost-eectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. J Public Health (Springer) 2010; 19 (2):103-11; http://dx.doi.org/10.1007/s10389-010-0377-z